The American Cancer Society revised its prostate cancer screening guidance to recommend routine PSA blood testing every two years for average-risk men aged 50 to 69. This replaces the approach laid out in 2010, when the society left testing largely to patient and physician discretion. Investigators reported the change reflects evidence that screening can reduce disease-specific deaths in certain men. The new advice returns PSA to a routine preventive role after years of debate over its specificity and downstream harms.
The guideline authors singled out higher-risk populations for earlier and more frequent surveillance. Black men and men with a strong family history of prostate cancer are advised to start annual PSA screening at age 45. The authors said they aim to reduce the disproportionate number of Black patients who present with advanced disease. The guidance explicitly intensifies screening for these groups compared with the average-risk recommendation.
The ACS clarified a numeric cutoff: a PSA level of 3.0 nanograms per milliliter or higher is considered elevated for men aged 45–69. James Eastham, a urologist quoted in the source, observed that many U.S. laboratories still report under 4.0 ng/mL as normal; the new threshold of 3.0 may prompt earlier referrals from primary care. The guideline text establishes this cutoff but the source did not present new outcome data tied to this specific threshold beyond expert commentary.
To limit overdiagnosis and overtreatment, the ACS recommended that clinicians obtain two elevated PSA readings before proceeding to additional testing. After two elevated results, the guidelines advise an MRI scan and/or testing for other biomarkers of prostate cancer prior to biopsy. The guidance gives clinicians flexibility — biomarker testing is an option for patients who cannot easily obtain MRI — but authors recommended MRI before biopsy when biomarker testing is abnormal. The document did not endorse a single secondary biomarker; the guideline authors said they will study biomarkers further to determine comparative effectiveness.
Screening beyond age 70 should be individualized. The ACS stated that the balance of benefits and harms becomes less clear after 70, so decisions should factor in health status and life expectancy. Screening should be discontinued at 80, or in men who are not expected to live another 10 years, according to the guidance. These stopping rules are intended to reduce harms from screening and treatment in men unlikely to derive survival benefit.
The guideline document acknowledged multiple available biomarkers but did not recommend one over another. William Dahut, an ACS official and contributing author, told reporters that ACS researchers plan to evaluate biomarkers more closely to identify which tests best predict aggressive disease. The source did not provide timelines or specific study designs for that planned research, nor did it specify preferred biomarker panels.
Outside clinicians described the recommendations as a balanced approach to early detection. Eastham told the source that recommending intermediate steps between an elevated PSA and biopsy should reduce unnecessary procedures and overtreatment. Patient advocates welcomed clearer routine screening advice. A prostate cancer survivor and advocate, quoted in the article, said the updated guidance strengthens longstanding calls to test more frequently, particularly in communities where screening uptake has been low.
The U.S. Preventive Services Task Force has not yet revised its stance in response to the recent evidence and continues to recommend individualized decision-making rather than routine, population-wide PSA screening. The USPSTF has announced an upcoming guideline update, but the source reported that, at the time of publication, the panel had not changed its recommendations. Because USPSTF grades influence insurance coverage, that pending update has practical implications beyond clinical debate.
The source noted that the ACS did not single out a preferred secondary biomarker and that researchers intend to study biomarkers further. The report did not include implementation details such as cost implications, projected screening uptake, or comparative outcome metrics tied to the 3.0 ng/mL cutoff. The USPSTF position remains different; the timing and conclusions of that panel’s forthcoming update were not reported. Those gaps—choice of biomarker, operational rollout, and the impact of divergent federal guidance—remain open questions documented in the source.